Bracco molecular imaging subsidiary Blue Earth Diagnostics said that a phase III clinical trial of its investigational radiohybrid PET imaging agent for prostate cancer is now underway.
The Lighthouse clinical trial is a multicenter, single-arm study in the U.S. and Europe that will evaluate the safety and diagnostic performance of the company's investigational prostate-specific membrane antigen-targeted radiohybrid PET imaging agent -- rhPSMA-7.3 (F-18) -- in men with newly diagnosed prostate cancer. The trial will determine the sensitivity and specificity of the agent for detecting pelvic lymph node metastases in comparison with surgical pathology, according to the company.
The initial patient in the study was dosed at RadNet's Liberty Pacific Advanced Imaging Center in Los Angeles, Blue Earth said.
